trastuzumab deruxtecan,ruxolitinib,trastuzumab
astrazeneca,daiichi sankyo,incyte,novartis
['rux,(-crux),(-trux)', 't-dxd', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'destiny,crc,02', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)']
 don't miss these exciting results at #asco23 #trastuzumab #deruxtecan #t-dxd in pts w/ her2+ #mcrc: primary results from the multicenter, randomized, ph2 destiny-crc02 study. 4/6 8:12 gmt-5 hall d2
#meded #oncology 
COR2ED bringing you Independent Medical Education developed 
by GI CONNECT, international experts in GI oncology